- Home
- MORN vs EXEL Comparison
MORN vs EXEL Comparison
Compare MORN & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MORN
- EXEL
- Stock Information
- Founded
- MORN 1984
- EXEL 1994
- Country
- MORN United States
- EXEL United States
- Employees
- MORN N/A
- EXEL N/A
- Industry
- MORN Investment Managers
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MORN Finance
- EXEL Health Care
- Exchange
- MORN Nasdaq
- EXEL Nasdaq
- Market Cap
- MORN 9.0B
- EXEL 10.4B
- IPO Year
- MORN 2005
- EXEL 2000
- Fundamental
- Price
- MORN $208.83
- EXEL $39.43
- Analyst Decision
- MORN Buy
- EXEL Buy
- Analyst Count
- MORN 2
- EXEL 22
- Target Price
- MORN $340.00
- EXEL $44.10
- AVG Volume (30 Days)
- MORN 349.0K
- EXEL 2.9M
- Earning Date
- MORN 10-29-2025
- EXEL 11-04-2025
- Dividend Yield
- MORN 0.83%
- EXEL N/A
- EPS Growth
- MORN 64.83
- EXEL 81.76
- EPS
- MORN 9.41
- EXEL 2.08
- Revenue
- MORN $2,347,400,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- MORN $8.04
- EXEL $9.14
- Revenue Next Year
- MORN $7.65
- EXEL $12.59
- P/E Ratio
- MORN $23.19
- EXEL $19.30
- Revenue Growth
- MORN 8.23
- EXEL 10.73
- 52 Week Low
- MORN $210.02
- EXEL $28.05
- 52 Week High
- MORN $365.00
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- MORN 34.83
- EXEL 55.28
- Support Level
- MORN $214.98
- EXEL $33.76
- Resistance Level
- MORN $222.00
- EXEL $40.63
- Average True Range (ATR)
- MORN 4.51
- EXEL 1.26
- MACD
- MORN 0.84
- EXEL 0.23
- Stochastic Oscillator
- MORN 27.21
- EXEL 90.90
About MORN Morningstar Inc.
Morningstar Inc is a provider of independent investment research to financial advisers, asset managers, and investors. The company focuses its operations on two core sectors: data and research. It offers data on investments such as mutual funds, stocks, exchange-traded funds, closed-end funds, separate accounts, and variable annuities. Further, the company tracks real-time market data of equity, derivative, currency exchanges, and other investments. In its research operation, Morningstar offers analyst research on passive and active mutual funds, alternative funds, and college saving plans. Morningstar's majority of the revenue is generated in the United States of America.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.